Rigel Pharmaceuticals Inc (RIGL) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
TAVALISSE Net Product Sales: $26.3 million, an 8% increase from Q3 2023. REZLIDHIA Net Product Sales: $5.5 million, a 107% increase from Q3 2023. Contract Revenues from Collaborations: $16.4 million, including $13 million from Kissei. Net Income: $12.4 million, compared to a net loss of $5.7 million in Q3 2023. Cash, Cash Equivalents, and Short-term Investments: $61.1 million at the end of the quarter. Warning! GuruFocus has detected 6 Warning Signs with RIGL. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Rigel Pharmaceuticals Inc ( NASDAQ:RIGL ) reported a 44% increase in net sales for the third quarter of 2024 compared to the same period in 2023, driven by strong performance across its commercial portfolio. The addition of GAVRETO to Rigel's portfolio contributed $7.1 million in net product sales in its first full quarter, indicating successful integration and transition of patie
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.MarketBeat
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
- Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionPR Newswire
- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at B. Riley from $17.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
RIGL
Earnings
- 11/7/24 - Beat
RIGL
Sec Filings
- 12/9/24 - Form 8-K
- 11/26/24 - Form 4
- 11/26/24 - Form 4
- RIGL's page on the SEC website